Maxillary sinus augmentation (MSA) through Schnei Q15 derian membrane elevation is one of the most predictable surgical procedures to reconstruct the atrophic posterior maxillary alveolar ridge. The successful placement of dental implant(s) in the jaws requires an adequate bone quantity (in vertical and horizontal dimension) and quality to ensure a high implant survival rate and to avoid surgical and aesthetic problems. MSA can be performed through two main approaches, namely lateral sinus lift and transalveolar sinus lift. In both approaches, the bone grafts are usually placed in a space created under the elevated maxillary sinus membrane. Ideally, bone grafting materials should provide or promote the three main features needed for a successful graft healing: osteoconduction to maintain space for new bone ingrowth, osteogenesis to recruit bone-forming cells, and osteoinduction to induce the differentiation of undifferentiated cells during bone regeneration or repair 1, 2 . However, no bone grafting material has all such features, except autogenous bone.
Different bone grafts have been used in MSA, each of them having their own advantages and drawbacks, and achieving different degrees of newly formed bone, residual particles, and soft tissue. These bone grafts include autogenous bone (AB), allografts (AG), xenografts (XG), alloplastic materials (AP), and composite grafts. Additionally, alternative adjuncts to bone grafting materials have recently been used in MSA, either alone or in combination with these bone grafts, such as autogenous platelet concentrates, recombinant growth factors (GFs), mesenchymal stem cells (MSCs), and recombinant bone morphogenetic protein 2 (BMP-2).
The evaluation of augmented maxillary grafted sinuses is performed by histomorphometric analysis of bone biopsies, which can determine the percentage of newly formed bone (NBF), residual graft (RG) particles, and connective tissue (CT) components of the whole field of view (biopsy) at the grafted site during the healing period 3, 4 . These parameters are clinically very important to assess the success of the sinus augmentation procedure: a greater NBF and lesser RG indicate a successful integration of the bone graft, which ultimately enhances implant survival 5 .
Many clinical studies and systematic reviews have investigated the success of the various bone grafting materials following MSA 3,6-9 . However, it is still unclear which bone grafting material, if any, provides the most predictable histomorphometric outcome in terms of new bone formation.
A systematic review with meta-analysis of comparative studies may help synthesize the evidence related to the debate on the most predictable grafting material. Previous systematic reviews and metaanalyses on histomorphometric outcomes of different graft materials used in sinus augmentation have suggested that autogenous bone alone can induce the highest amount of new bone formation compared to the other materials, especially in the short term ( 6 months) 4, 5 . Nevertheless, a combination of autogenous bone and xenografts, as well as xenografts alone and mixtures of tricalcium phosphate and hydroxyapatite may represent valid alternatives to autogenous bone when donor site morbidity is a concern 10 . Traditionally, a direct meta-analysis only allows the comparison and pooling of data from head-to-head separate but similar studies. Thus, comparisons are limited to such clinical trials. Hence, one of the main limitations of previous meta-analyses is that the effect of some bone graft materials could only be evaluated if they were compared directly with specific control materials and if there were multiple studies in which the same comparison was performed. So, in the absence of direct comparisons, the potential benefit of a given material remains unknown.
The network meta-analysis (NMA) has emerged as a suitable tool for comparing two interventions that have not been compared directly in a head-to-head clinical trial and also offers the chance to run a collective assessment of variable interventions in a single study 11 . Thus, on comparison of NMA to conventional metaanalysis, the former offers the following advantages: it produces an estimate of effect among all compared groups, enhances the precision of effect estimates, ranks different treatments, and improves generalizability [12] [13] [14] .
Statistically, a NMA can be conducted using either a frequentist or Bayesian approach [15] [16] [17] . The frequentist NMA is what researchers will commonly encounter in single randomized controlled trials (RCTs) and conventional direct metaanalyses. The results of the frequentist NMA are presented as a point estimate (effect measure such as the odds ratio, risk ratio, mean difference, or standardized mean difference) with the 95% confidence interval (CI), whereas the results of the Bayesian NMA are reported as the point estimate with a 95% credibility interval (CrI) 16 .
There are currently no published RCTs comparing the following different bone grafts with regard to histomorphometric outcomes of the different bone grafting materials after MSA: (1) AB alone and the combination of XG and AP, AG and XG and BMP-2; (2) XG and the combination of AB with AP and AG with XG; (3) AP to AB in combination of AP with AG or XG or BMP-2 alone; (4) AG to a mixture of XG with AP, AB with AP, AB with XG or GFs; (5) AB in combination with AP or XG in combination with AG versus XG mixed with AP or AG. Thus, a NMA of RCTs was conducted to make comparisons among the different bone grafting materials and to rank the ideal bone grafting materials according to their histomorphometric performance.
The following hypotheses were postulated: (1) there is no difference in histomorphometric outcomes between the different bone grafting materials after MSA; (2) the alternative hypothesis, i.e. that with respect to autogenous bone alone, the use of acellular osteoconductive bone substitute materials will result in lower NBF and higher RG and CT when compared to the combination of osteoconductive bone substitute materials plus osteogenic and/or osteoinductive bone grafts;
(3) autogenous bone shows the fastest healing time and the highest NBF at any given time, among the grafting materials investigated.
The specific aims of this NMA were to challenge these hypotheses and to identify the best bone grafting material, providing the greatest NBF and lowest RG and CT following MSA.
Materials and methods

Protocol and registration
A NMA of RCTs was conducted according to the PRISMA Extension Statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions (Supplementary Material File 1 shows the PRISMA-NMA  checklist) 18 . The protocol is registered in the PROSPERO database (systematic review registration CRD42018089357) 19 .
Search strategy
Relevant RCTs, in any language and with any publication date, were retrieved by systematic search of MEDLINE, Embase, and the Cochrane Central Registry of Controlled Trials (CENTRAL) from the date of inception of each database (Supplementary Material File 2).
Eligibility criteria
Inclusion criteria
The following inclusion criteria were adopted based on the PICOTS process: patients (P) were those with an atrophic posterior maxilla that required augmentation of the maxillary sinus using different biomaterials, with immediate or delayed dental implant placement; the intervention (I) was MSA using one of the following bone grafting materials: allograft (AG), xenograft (XG), alloplastic graft (AP), autogenous bone and allograft (AB + AG), autogenous bone and xenograft (AB + XG), autogenous bone and alloplastic graft (AB + AP), allograft and xenograft (AG + XG), any bone graft associated with GFs, any graft associated with recombinant BMP-2, any graft associated with MSCs; the comparator (C) was autogenous bone (AB); the primary outcomes (O) were histomorphometric outcomes, namely the percentage NBF, RG particles, and CT in the whole field of view; the time (T) was all healing times, including 3, 4, 6, and 9 months and more than 1 year (short to intermediate term defined as <6 months and long term defined as !6 months); the study design (S) was RCTs, including split-mouth and parallel studies, that reported the outcomes of interest.
Exclusion criteria
The following exclusion criteria were applied: (1) studies with none of the basic data required to perform a meta-analysis, such as the mean percentage of NB, RG, and CT, standard deviation, and number of biopsies; (2) non-randomized clinical studies, case series, retrospective studies, and cohort studies; (3) review articles; (4) animal or in vitro studies; (5) publications using duplicated data.
Data extraction
Data were extracted from the included studies according to a predetermined datasheet. Two reviewers (A.A. and B.A.) independently tested the datasheet using two randomly chosen studies, to ensure the consistency of the data extraction process. After adjustment of the extraction form, the data were extracted independently in duplicate. In the case of disagreement, a third reviewer (E.A.) was consulted. The following information was extracted from each study: main features of the study and participants (authors, study design, patients' age and sex), type of grafting material, membranes used (if any), number and characteristics of biopsy samples, timing of biopsy, timing of implant surgery, histomorphometric outcomes assessed.
Assessment of the risk of bias
Two authors (B.A and N.A.) independently evaluated the risk of bias of each included study using a modified version of the Cochrane tool for risk of bias assessment 20, 21 . The domain regarding blinding of participants and personnel (performance bias) was not considered, because in MSA, neither the surgeon nor the patient can be efficiently masked to the bone graft material used, especially if it is autogenous bone.
Data synthesis
Network geometry
The geometry of the network was represented by a spider web-like plot to show the connections between the different studies using different graft materials. Before undertaking the NMA, potential effect modifiers were identified, such as the duration of follow-up and the risk of bias. Hence, distinct network plots were created, in which the potential effect modifiers were highlighted in different colours, in order to guarantee the balance across the comparisons 22 .
Measures of treatment effect
In the meta-analysis, the weighted mean difference (WMD) was calculated for continuous outcomes. The results of the NMA for each possible pair of graft materials were reported as a summary of the relative effect sizes. In split-mouth studies, the statistical unit of analysis was the augmented sinus, while it was the patient in parallel studies.
Assessment of transitivity across comparisons
In order to assess the transitivity across graft materials, the distribution of the following potential effect modifiers was evaluated: age, sex, and type of core biopsy (crestal or lateral core biopsy).
Methods for direct treatment comparisons
A traditional pairwise meta-analysis (PMA) of all possible direct comparisons was also undertaken 23 . A random-effects model was chosen, using the software Comprehensive Meta-Analysis version 2 (Biostat, Inc., Englewood, NJ, USA).
Methods for mixed and network comparisons
The comparisons were performed through the tool ''Network meta-analysis'' in Stata Statistical Software Release 14, 2011 (Sta-taCorp., College Station, TX, USA) 24, 25 . The ''mvmeta'' command was used 26 , together with self-programmed Stata routines (available at http://www.mtm.uoi.gr).
Assessment of statistical heterogeneity
Assumptions when estimating the heterogeneity: In the traditional PMA, distinct heterogeneity variances were assessed for any pairwise comparison. Conversely, a single, common estimate of the heterogeneity variance across all individual comparisons was assumed in the NMA 27 .
Assessment of statistical inconsistency
Local approaches for assessing inconsistency: The loop-specific approach was used to assess the presence of inconsistency locally in each closed loop of the network. The difference between direct and indirect estimates was assessed for any specific comparison in the loop (inconsistency factor). Hence, the size of the inconsistency factors and the 95% CI were used to estimate the inconsistency at the level of each loop. Moreover, a common heterogeneity estimate was assumed within each loop 28 . A forest plot was created with the ''ifplot'' command in Stata to summarize the results of this approach.
Global approaches for evaluating inconsistency: To verify the assumption of consistency in the overall network, the 'design-by treatment' model with the ''mvmeta'' command in Stata was used, as described by Higgins et al. [28] [29] [30] .
Relative treatment ranking
The ranking probabilities were estimated for all of the grafting materials at each possible rank associated with any material. Then, the hierarchy of grafting materials was calculated using the 'surface under the cumulative ranking' (SUCRA) curve, as well as the mean ranks 31 . The SUCRA may also be evaluated as the probability of a given treatment to be ranked first without uncertainty. The rank-heat plot was done to visualize and show the grafting material hierarchy across the multiple outcomes of interest 32 .
Subgroup and meta-regression analysis
This was done in order to identify the possible sources of inconsistency. All biopsies were divided according to the duration of the healing period into the following subgroups: (1) <6 months, and (2) !6 months. Hence, subgroup analysis based on the healing time was undertaken for all outcomes.
In order to investigate whether the healing time had an effect on NBF, metaregression analysis was done considering the overall mean percentage of NBF (for 52 RCTs) and the healing times at which core biopsies were harvested for all of the studies. Additionally, meta-regression analysis was done based on subgroup analysis for those groups that included a larger number of RCTs for the outcome of NBF.
Sensitivity analysis
In order to make certain that the assumptions made in the analysis do not represent a bias for the NMA outcomes, and to ensure that a sufficient number of studies was found, the NMA was repeated after the exclusion of (1) studies in which fewer than 10 core biopsies were analyzed; (2) groups consisting of fewer than five studies, namely allografts combined with xenografts (only one RCT) and xenografts combined with alloplastic grafts (three RCTs); and (3) studies with a high risk of bias.
Assessment of publication bias
In order to assess the network-wide publication bias and the effect of small-sized studies for outcomes with at least 10 studies in the network, a comparison-adjusted funnel plot was constructed 33 . Grafting materials were ordered chronologically from the oldest to the newest studies 34 . Fig. 1 shows a flow diagram of the article screening process for inclusion in the review and in the NMA. The electronic search strategy yielded a total of 350 studies from all databases. Fifteen additional studies were identified from other sources (hand-search). Of the 365 articles, 102 were duplicates and were removed. Based on the titles and abstracts, a further 100 articles were excluded. The full-text articles of the remaining 163 eligible studies were evaluated by two reviewers (N.A. and B.A.) for inclusion. After full-text analysis, 111 studies were excluded because they did not meet the inclusion criteria. Finally, a total of 52 RCTs met the inclusion criteria and were submitted to review .
Results
Study selection
Presentation of network geometry
A network diagram of all eligible comparisons for the primary outcome is presented in cluded in the network diagram (AB, AG, XG, AP, AB + XG, AB + AP, AG + XG, XG + AP, GFs, BMP-2, and MSCs). Ten comparisons between the different bone grafting materials and AB were considered.
Summary of network geometry
For the outcome of overall NBF, the total sample consisted of 1483 biopsies in 52 RCTs on MSA . The grafting materials were AB alone (n = 16 trials; 215 biopsies) 37, 39, 41, 43, 44, 52, 54, 58, 65, 68, 71, 73, 76, 80, 81, 83 , AG alone (n = 6 trials; 78 biopsies) 47 , AB + XG (n = 7 trials, 113 biopsies) 36, 39, 52, 66, 69, 70, 86 , AB + AP (n = 4 trials, 51 biopsies) 58, 65, 72, 81 , AG + XG (n = 1 trial, 17 biopsies) 74 , XG + AP (n = 3 trials, 40 biopsies) 35, 45, 46 , GFs (n = 12 trials, 145 biopsies) 37, 40, 41, 50, 54, 61, 62, 68, 71, 78, 79, 85 , BMP-2 (n = 5 trials, 116 biopsies) 47, 53, 55, 56, 72 , and MSCs (n = 5 trials, 80 biopsies) 63, 64, 69, 70, 82 . AB alone was used as the comparator arm.
Study characteristics
The characteristics of the RCTs, patients, and biomaterials are summarized in Table 1 .
Risk of bias within included studies
Twenty RCTs had a low risk of bias, 28 RCTs had an unclear risk of bias, and four RCTs showed a high risk of bias. More details are shown in Supplementary Material File 3.
Results of individual studies
A summary of individual data for all outcomes of interest (NBF, RG, and CT), including mean percentages, standard deviations, and the number of core biopsies for all groups, is presented in Supplementary Material File 4.
Synthesis of results
New bone formation (NBF)
With regard to the overall mean percentage of NBF (over a duration of 3-15 months), a total of 1483 core biopsies in 52 RCTs consisting of 11 groups were included . There was a statistically significant difference between AP and AB (WMD = À8.04%, 95% CI À 12.11 to À3.97) and between XG and AB (WMD = À4.49%, 95% CI À 8.91% to 0.08%), in favour of AB ( Fig. 3 ).
For the mean percentage NBF with a healing time <6 months (range 3-5 months), a total of 645 biopsies in 19 RCTs consisting of 10 groups were included 35, 37, 39, 45, 46, 50, 55, 56, 58, 64, 66, [68] [69] [70] [71] [72] [73] 81, 82 . NBF was significantly higher in AB compared to AP alone (WMD = À10.66%, 95% CI À 16.38% to À4.94%) and XG alone (WMD = À7.93%, 95% CI À 15.11% to À0.75%).
There was no statistically significant difference between AB alone and AB + AP (WMD = 0.42%, 95% CI À 5.41% to 6.24%), AG alone (WMD = À7.93%, 95% CI À 17.39% to 1.53%), MSCs (WMD = À8.17%, 95% CI À 16.38% to 0.04%), AB + XG (WMD = À7.62%, 95% CI À 15.35% to 0.10%), BMP-2 (WMD = À1.48%, 95% CI À 9.78% to 6.81%), XG + AP (WMD À 3.05%, 95% CI À 11.24% to 5.13%), or GFs (WMD = 1.69%, 95% CI À 3.38% to 6.76%) ( Fig. 4 ).
Sensitivity analysis based on subgroup analysis showed no significant increase in the amount of NBF at augmented sites when GFs were added to AB. However, there was a significant increase in NBF when using GFs in conjunction with XG (P = 0.001). These findings were derived from seven direct RCTs 50, 61, 62, 70, 78, 79, 85 .
For the mean percentage NBF with a healing time of !6 months, a total of 872 biopsies were included in 37 RCTs consisting of 10 groups. These RCTs compared different bone grafting materials and investigated the amount of new bone after at least 6 months following MS Q16 A 36, 38, [40] [41] [42] [43] [44] [47] [48] [49] [50] [51] [52] [53] [54] 57, [59] [60] [61] [62] [63] [64] [65] 67, [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] . There was statistically significant superiority of AB with respect to AP alone (WMD = À7.06%, 95% CI À 12.59% to À1.52%). There was no significant difference between AB and all other groups ( Fig. 5 ).
Residual graft particles (RG)
With regard to the overall mean percentage RG (over a duration of 3-15 months), a total of 1159 biopsies in 38 RCTs consisting of 11 groups were included 35 . There was a statistically significant difference between AB and XG (WMD = 9.62%, 95% CI 0.40% to 18.84%), but not with respect to the other groups ( Fig. 6 ).
For the mean percentage RG with a healing time of <6 months (range 3-5 months), a total of 509 biopsies in 15 RCTs involving 10 groups were included 35, 36, [45] [46] [47] 55, 56, 64, 66, 69, 70, 72, 73, 81, 82 . There was no statistically significant difference between AB and any of the other nine groups (Fig. 7) .
For the mean percentage RG with a healing time of !6 months, a total of 616 biopsies in 27 RCTs involving 10 groups were included 40 significant difference between AB alone and AP alone (WMD = 12.03%, 95% CI 3.04% to 21.03%), XG alone (WMD = 14.62%, 95% CI 4.25% to 24.98%), and GFs (WMD = 12.32%, 95% CI 0.04% to 24.60%). There was no statistically significant difference between AB alone and the other groups (Fig. 8 ).
Connective/soft tissues (CT)
With regard to the overall mean percentage (%) CT (over a duration of 3-9 months), a total of 1038 biopsies in 33 RCTs consisting of 11 groups were included 35,36,40,42-46, 48-51,53,55-57,59,62-66,69,70,72-75,80,82,83,85,86 .
There was a statistically significant difference between AB alone and the following: XG + AP (WMD = À14.62%, 95% CI À 27.37% to À1.87%), AP (WMD = À12.22%, 95% CI À 20.28% to À4.16%), MSCs (WMD = À12.05%, 95% CI À 22.84% to À1.26%), and XG (WMD = À11.06%, 95% CI À 19.05% to À3.08%).
There was no statistically significant difference in the amount of CT after MSA between AB alone and AB + XG (WMD = À10.71%, 95% CI À 21.51% to 0.09%), AB + AP (WMD = À1.46%, 95% CI À 17.28% to 14.35%), GFs (WMD = À8.39%, 95% CI À 19.52% to 2.73%), BMP-2 (WMD = 0.63%, 95% CI À 11.43% to 12.69%), AG alone (WMD = À1.60%, 95% CI À 11.67% to 8.47%), or AG + XG (WMD = 11.65%, 95% CI À 6.81% to 30.11%) ( Fig. 9) .
With regard to the mean percentage CT over a healing time of <6 months (range 3-5 months), a total of 474 biopsies in 14 RCTs involving 10 groups were included 35, 36, 45, 46, 50, 55, 56, 64, 66, 69, 70, 72, 73, 82 . There was a statistically significant difference between AB alone and the following: XG + AP (WMD = À18.20%, 95% CI À 25.90% to À10.49%), AP (WMD = À17.35%, 95% CI À 32.32% to À2.37%), BMP-2 (WMD = À14.75%, 95% CI À 23.02% to À6.48%), GFs (WMD = À13.83%, 95% CI À 27.27% to À0.39%), MSCs (WMD = À11.42%, 95% CI À 19.81% to À3.02%), XG (WMD = À11.13%, 95% CI À 16.99% to À5.27%), and AB + XG (WMD = À9.54%, 95% CI À 16.88% to À2.21%). There was no statistically significant difference between AB + AP and AB alone (WMD = À16.35%, 95% CI À 40.63% to 7.93%) or between AG alone and AB alone (WMD = À7.91%, 95% CI À 23.73% to 7.92%) ( Fig. 10) .
For the mean percentage CT over a healing time of !6 months, a total of 564 biopsies in 22 RCTs involving 10 groups were included 40, [42] [43] [44] [48] [49] [50] [51] 53, 57, 59, [62] [63] [64] [65] 74, 75, 80, 82, 83, 85, 86 . The CT% in the BMP-2 group was significantly lower than that in the AB alone group (WMD = 23.85%, 95% CI 6.42% to 41.27%). There was no significant difference between the AB alone group and all other groups (Fig. 11 ).
Exploration for inconsistency
Loop-specific tests did not detect any statistical inconsistency between direct and indirect evidence (local inconsistency). All confidence intervals for ratio of odds ratios (RoRs) were compatible, with zero inconsistency (RoR = 1) for all study out-
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Treatment ranking
NBF
According to the SUCRA ranking, the most effective bone grafting material that increased NBF after MSA at a healing time ranging from 3 months to 15 months was AG + XG (95%, very low quality evidence), followed by GFs (69.9%, low quality evidence), AB alone (69.8%, moderate quality evidence), AB + AP (68.3%, low quality evidence), XG + AP (59.1%, very low quality evidence), MSCs (50.8%, low quality evidence), BMP-2 (40.3%, low quality evidence), AG alone (35.9%, low quality evidence), XG alone (28.8%, moderate quality evidence), AB + XG (28.1%, low quality evidence), and AP alone (4.3%, moderate quality evidence) ( Fig. 12 ; Supplementary Material File 6).
RG
According to the SUCRA ranking, the most effective bone grafting material that decreased RG after MSA at a healing time ranging from 3 months to 15 months was BMPs (88.8%, very low quality evidence), followed by AB alone (81.5%, moderate quality evidence), AB + AP (58.9%, very low quality evidence), AG + XG (55.9%, very low quality evidence), AG alone (51.2%, low quality evidence), AB + XG (50.1%, low quality evidence), GFs (45.1%, very low quality evidence), XG + AP (42.3%, very low quality evidence), AP alone (34.7%, moderate quality evidence), XG alone (22%, moderate quality evidence), and MSCs (19.8%, low quality evidence) ( Fig. 12 ; Supplementary Material File 6).
CT
According to the SUCRA ranking, the most effective bone grafting material that decreased CT after MSA at a healing time ranging from 3 months to 9 months was XG + AP (84.7%, low quality evidence), followed by AP alone (77.7%, moderate quality evidence), MSCs (76.1%, low quality evidence), XG alone (71.1%, moderate quality evidence), AB + XG (68.6%, low quality evidence), GFs (56.8%, very low quality evidence), AB + AP (33.1%, low quality evidence), AG alone (30.1%, low quality evidence), AB alone (23.6%, low quality evidence), BMP-2 (23.1%, low quality evidence), and AG + XG (5.1%, very low quality evidence) ( Fig. 12; Supplementary Material File 6) .
According to the SUCRA ranking, the bone grafting materials with the highest probability of achieving the highest NBF %, the lowest RG%, and the lowest CT% up to 6 months after MSA were, respectively, AG + XG (95% probability), BMP-2 (88.8%), and XG + AP (84.7%) ( Fig. 12 ; Supplementary Material File 6).
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Al-Moraissi et al. 6 . Forest plot of the network meta-analysis for overall residual graft (RG) particles: percentage weighted mean difference (WMD) with 95% confidence interval (CI) and 95% predictive interval (PrI).
Meta-regression analysis
Meta-regression analysis showed that there was a negative and insignificant relationship between the overall mean percentage of NBF (52 RCTs) and healing time (r = À0.35, 95% CI À 1.2 to 0.54; P = 0.342). Meta-regression analysis based on subgroup analysis revealed that there was a negative and statistically insignificant association following AB (r = À0.75, 95% CI À 3.1 to 1.66; P = 0.515), AG (r = À0.61, 95% CI À 10.6 to 9.4; P = 0.874), and GFs (r = À1.3, 95% CI À 4.8 to 2.1; P = 0.405). However, there was a positive and statistically insignificant association following XG (r = 0.031, 95% CI À 2.2 to 2.2; P = 0.977), AP (r = 0.91, 95% CI À 2.6 to 4.4; P = 0.590), BMP-2 (r = 0.64, 95% CI À 3.9 to 5.2; P = 0.689), MSC (r = 5.9, 95% CI À 9.9 to 21.7; P = 0.358), and AG+XG (r = 1.3, 95% CI À 3.9 to 6.7; P = 0.531).
Confidence of evidence
For all outcomes (NBF, RG, and CT), the quality of evidence of NMA estimates for all comparisons ranged from moderate to very low. For various comparisons, the evidence was downgraded because of study limitations, imprecision, or incoherence. Overall confidence of evidence for outcomes of interest was as follows: moderate quality of evidence for NBF and low quality for outcomes of RG and CT. More details about quality of evidence for all outcomes based on the GRADE system are summarized in Supplementary Material File 7.
Funnel plot and publication bias
The funnel plot for the outcome of NBF is shown in Fig. 13 . Scatters in the funnel plot were almost symmetrical, indicating the absence of a small size effect and publication bias.
Sensitivity analysis
After excluding studies consisting of fewer than 10 core biopsies, comparisons consisting of fewer than five RCTs (AG + XG, one RCT; XG + AP, three RCTs; AB + AP, four RCTs), and studies with a high risk of bias 36, 40, 44, 50 , the overall evidence did not change.
Discussion
There is still no consensus regarding the best grafting materials in dental implantology, particularly for the MSA procedure. NMA allows a comparison of the results of treatments from RCTs with both indirect and direct comparisons, in contrast to the traditional meta-analysis, which is only based on the latter. The purpose of the current NMA, based on RCTs on MSA, was to assess the difference in histomorphometric outcomes with the use of different bone grafting biomaterials. The alternative hypothesis of a better performance of AB as compared to other materials, regarding NBF, was confirmed only for a healing time shorter than 6 months. For a healing time of 6 months or longer, the null hypothesis could generally be accepted for all histomorphometric parameters considered. From the biological perspective of bone grafting materials, the present study revealed moderate quality evidence suggesting that the application of acellular osteoconductive scaffold bone grafts alone, such as XG or AP, resulted in the lowest NBF and highest RG and CT in MSA, when compared to osteogenic and/ or osteoinductive bone grafts.
Autogenous bone vs. Allografts
When comparing each graft material to autogenous bone, some considerations can be made. For autogenous bone vs. allografts, the absence of a significant difference in NBF (moderate quality evidence) is compatible with some previous studies 59 and differs from others 58, 72 . NMA showed no significant difference in RG% between AG and AB (low quality evidence), in agreement with other studies and indicating similar resorption rates for the two materials 5, 83 .
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Autogenous bone vs. Xenografts
Autogenous bone showed higher NBF than xenografts at a healing time <6 months 43, 52, 73 . However, when the healing time was !6 months, no statistically sig-nificant difference was found, in spite of a weak trend in favour of AB (moderate quality evidence). This would suggest that graft healing proceeds faster with AB, but with time the total NBF tends to be similar. Recently published systematic reviews with meta-analyses have reported a similar finding 5, 10, 73 . Notably, NMA showed that XG at different healing times resulted in a significantly greater RG% and lower CT% than AB alone, up to 6 months, indicating a slower resorption rate than for AB.
Autogenous bone vs. Alloplastic materials
The performance of AP biomaterials was found to be inferior to that of AB at any healing time (moderate quality evidence). Previous reports are in agreement with the present study 5, 44, 84 . AP biomaterials are the least effective biomaterial in terms of increasing NBF following MSA. It may be hypothesized that the very low NBF when using AP as compared to AB, at different healing times, depends on the higher resorption rate of AP. This has been suggested for combinations of hydroxyapatite with tricalcium phosphate, due to osteoclast recruitment induced by tricalcium phosphate 87 .
Autogenous bone vs. Combination of AB with XG
Based on the results derived from PMA and NMA (low quality evidence), a combination of AB and XG has no benefits with regard to the amount of NBF when compared to AB alone. A recent study reported the same result 5 . Any reduction in NBF following the use of a mixture of AB and XG might be explained by the different proportions of XG or AB used, the different donor sites of AB used, and by a difference in bone resorption rate between AB and XG. Consequently, all of these factors could lead to a decrease in percentage of NBF. Similarly, the results of the present study showed no advantage in terms of NBF when AB is combined with AP as compared to AB alone, in contrast to the findings of another systematic review 5 .
Autogenous bone vs. Combination of XG with AG
There were no RCTs directly comparing AB alone and the combination of XG and AG. Although the amount of NBF in the maxillary sinuses augmented using a mixture of XG and AG was higher than that for AB at the healing time of 6 months, the difference was not statistically significant (due to large variability and low sample size) and the quality of evidence was very low. This composite graft was ranked as the first (95%) biomaterial likely to increase NBF formation at 6 months, but only one RCT was included in the NMA 74 . So, more RCTs are needed to assess histomorphometric outcomes using a mixture of XG + AG vs. AB or any biomaterials before drawing conclusions.
Autogenous bone vs. Mixture of xenografts and alloplastic materials
No RCTs directly compared AB to XG combined with AP biomaterials. Very low quality of evidence through indirect evidence showed that there was some advantage when combining XG to AP biomaterials at a healing time of 4-5 months. Two RCTs investigated XG alone vs. XG with AP 19, 45 . There was a significant increase in NBF for composite bone graft (XG and AP) vs. XG alone (P = 0.001).
Autogenous bone vs. Different bone grafts plus GFs
Five RCTs directly compared AB alone with combinations of different grafting biomaterials plus GFs (including platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and recombinant platelet-derived growth factor (PDGF)) at a healing time ranging from 4 to 8 months 37, 41, 54, 68, 71 . No statistically significant difference was found by either PMA (P = 0.84) or NMA (low quality of evidence). This result is consistent with several published reports 10, 68, 71, 88 . Autologous PRP, PRF, or rhPDGF has been applied in regenerative medicine as an adjunct to osteoconductive materials such as AB, XG, and AP biomaterials. Thus, it is clinically relevant to assess which biomaterials combined with GFs may enhance NB formation. Interestingly, the combination of GFs with different bone grafts showed the greatest probability of producing the highest NBF (88.3%, low quality evidence) and the lowest RG (88%, very low quality evidence) after MSA at a healing time of <6 months.
Autogenous bone vs. BMP-2/different bone grafts plus MSCs
There is a lack of RCTs directly comparing AB vs. BMPs as well as directly investigating the effect of the adjunctive use of MSCs with autogenous grafts. Three RCTs directly assessed NBF comparing XG and BMPs [53] [54] [55] , and another three RCTs directly compared XG to XG plus MSCs, with follow-up shorter than 6 months 63, 64, 82 . In both cases, PMA and NMA (low quality of evidence) found no statistically significant difference. Such results are in agreement with those of previous studies 63, 64, 82, 89, 90 . Nevertheless, the application of MSCs in combination with any osteoconductive biomaterials (xenografts or autograft with xenografts) resulted in a greater amount of NBF when the healing time was more than 6 months, suggesting that remodelling may require a longer time when using these materials, in spite of the association with MSCs. Meta-regression analysis showed that there was a negative and insignificant relationship between NBF and healing time. Again, this is further evidence supporting the assumption of consistency and absence of transitivity in the present study.
Interestingly, meta-regression analysis for those subgroups that included a larger number of RCTs revealed that there was a negative and statistically insignificant association following grafting with AB. Conversely, a positive but statistically insignificant association was found after grafting with XG and AP. Similar results using a simple correlation analysis within a PMA were reported previously by Handschel et al. in 2009 4 . In spite of a negative correlation, AB maintains a higher NBF than other materials at any given time, thus a variation in healing time would not affect the percentage of NBF. This finding would suggest that new bone is formed early with AB and is slowly resorbed. In contrast, XG and AP showed a positive relationship between NBF and healing time, suggesting that for these bone grafts, new bone deposition proceeds slowly and with a delay as compared to AB.
Limitations and strengths of the systematic review
This systematic review has several limitations: (1) both PMA and NMA were performed according to the study level data, because the studies included did not report individual patient data. This is a common limitation encountered when performing systematic reviews and meta-analyses. (2) Included studies contained some confounding factors that may have affected the results, such as (a) possible inaccuracies in differentiating between the amount of NBF and RG particles in the AB group because of biological similarities between them; (b) differences in the technique for taking core biopsies, volume of the core (diameter and height), and sites of the biopsy (apical, central, or crestal). All of these factors could have had an impact on histomorphometric outcomes. (3) Variation or omission in reporting the preoperative residual bone height in the included studies, which could represent a co-variable affecting the amount of NBF, as a residual bone ridge with thicker cortical and cancellous layers would provide a better nourishment wall to the grafted sinus than thin ridges. (4) The amount of vestibular-palatine distance, because the greater it is, the higher the percentage of connective tissue, which in turn could cause a decrease in the amount of NBF 91 . (5) Including and pooling different subtypes of each main biomaterial category (AG, XG, and AP) in separate groups regardless of their processing method and composition, which might have influenced the histomorphometric performance evaluation. (6) Using different sources of AB (e.g. intraoral and extraoral) and different proportions of biomaterials in the case of composite grafts (AG + AP, AG + XG, AG + AP, and AG + XG). (7) Variations in healing time among the included studies. To partially overcome this confounding factor, a subgroup analysis was conducted based on the healing time. Additionally, meta-regression analysis was performed to identify whether healing time influenced the outcomes of interest. (8) Several of the included studies used a barrier membrane over the lateral window osteotomy, to cover the graft, while others did not use a membrane or did not report whether they used a membrane or not. (9) In this study it was assumed that the lower the CT% the higher the fraction of graft able to provide support (either new bone or residual graft). However, the definition of CT% is generic in most studies, as the detailed composition of this fraction is rarely provided. Typically, connective tissue is mostly composed of collagen type I fibrils; these may become mineralized and turn into mature bone tissue with time, leading to an increase in the total bone volume in the graft 92, 93 . However, there is the possibility that this fraction is composed of other types of fibrous tissue, or adipose tissue or other tissues, that may limit the capability of the graft to provide greater support in the future. An additional potential limitation of this study is that very few RCTs were found for some groups, such as AG + XG (one RCT) and XG + AP (two RCT Q17 s). So, even though the healing process occurs independently of the type of study in which the patient is involved, the present results regarding the relative performance of these composite grafts are not conclusive and should be interpreted with great caution.
Strengths of this study are (1) the novel performance of an NMA of RCTs with a clinical research question concerning the most effective biomaterials in term of histomorphometric outcomes after MSA.
(2) This systematic review included the application of new NMA methods, which simultaneously pooled direct and indirect evidence from RCTs. (3) This study included a high number of RCTs due to a comprehensive literature search. (4) To assess the certainty of confidence derived from the results of this study, the GRADE rating system was used, which allows the identification of inconsistency. (5) A sensitivity analysis was performed after excluding studies comparing fewer than 10 biopsies, studies with a high risk of bias, and co-interventions including fewer than five RCTs. (6) Meta-regression analysis was conducted to assess the effect of healing time (effect modifier) on the amount of NBF.
Conclusions
In conclusion, most of the results of this NMA are in agreement with those of other systematic reviews that have addressed some of the specific comparisons and aspects separately. For example, the healing time has a prominent effect on new bone formation, especially when using biomaterial characterized by a slow resorption rate such as xenografts, which need longer healing times to achieve a high NBF compared to materials with a faster resorption rate. In fact, autogenous bone showed the best performance only when the healing time was shorter than 6 months, while for a longer healing time the majority of materials achieved similar histomorphometric results. The clinical implication of this finding is that grafting with autogenous bone is recommended when implant rehabilitation is planned within 6 months of the grafting procedure. Also, the addition of autogenous bone, GFs, or MSCs to any biomaterial may increase the healing rate. The combination of alloplastic materials and autogenous bone represents a satisfactory alternative to autogenous bone alone to achieve high NBF in combination with reduced morbidity. If harvesting site morbidity is a concern, many alternative graft materials can be used as they may achieve results similar to AB, but healing times longer than 6 months are advised.
NMA therefore represents a powerful tool able to overcome some of the limitations of standard PMA, in particular the need for head-to-head RCTs, in order to draw conclusions on the relative efficacy of alternative treatments.
